Although no studies have been described relating the influence of genetic alterations in the CD52 gene to the effectiveness of alemtuzumab in patients with MS, an association was observed in 108 Caucasian kidney transplant patients in Poland, where the rs1071849 (A>G; Asn40Ser) and rs17645 (A>G; Ile41Met) polymorphisms may have affected alemtuzumab response by altering the effectiveness of recognition of the C-terminal part of CD52 [86]. The gene discussed is CD52; the disease is myeloid sarcoma.